www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

phospho-LATS1+LATS2 (Thr1079 +Thr1041) Rabbit pAb

Catalog Number:	bs-7913R
Target Protein:	phospho-LATS1+LATS2 (Thr1079 +Thr1041)
Concentration:	1mg/ml
Form:	Liquid
Host:	Rabbit
Clonality:	Polyclonal
Isotype:	IgG
Applications:	WB (1:500-2000), IHC-P (1:100-500), IHC-F (1:100-500), IF (1:100-500), ELISA (1:5000-10000)
Reactivity:	Human, Mouse, Rabbit (predicted:Rat, Pig, Cow, Chicken, Dog, Horse)
Predicted MW:	124 kDa
Entrez Gene:	26524
Swiss Prot:	Q9NRM7
Source:	KLH conjugated synthesised phosphopeptide derived from human LATS1 around the phosphorylation site of Thr1079: EF(P-T)FR.
Purification:	affinity purified by Protein A
Storage:	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:	This gene encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The protein localizes to centrosomes during interphase, and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a co-repressor of androgen-responsive gene expression. [provided by RefSeq].

VALIDATION IMAGES



Sample: Hela(Human) Cell Lysate at 30 ug Primary: Anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) (bs-7913R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 124 kD Observed band size: 124 kD



Sample: Cerebrum (Mouse) Lysate at 40 ug Primary: Anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) (bs-7913R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 124 kD Observed band size: 124 kD



Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-LATS1+LATS2 (Thr1079 +Thr1041)) Polyclonal Antibody, Unconjugated (bs-7913R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.



phosphopeptide non phosphopeptide

PRODUCT SPECIFIC PUBLICATIONS

[IF=9.7] Wei Zheng. et al. An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC. CANCER LETT. 2024 Apr;588:216813 IHC ; Rat . 38499266

[IF=10.317] Qi Yang. et al. A novel biodegradable external stent regulates vein graft remodeling via the Hippo-YAP and mTOR signaling pathways. Biomaterials. 2020 Nov;258:120254 WB ; Rat . 32805499

[IF=8.579] Lixia Chen. et al. CSRP2 suppresses colorectal cancer progression via p130Cas/Rac1 axis-meditated ERK, PAK, and HIPPO signaling pathways.. Theranostics. 2020; 10(24): 11063–11079 WB ; Human . 33042270

[IF=7] Li Mengzhi. et al. NRP1 transduces mechanical stress inhibition via LATS1/YAP in hypertrophic scars. CELL DEATH DISCOV. 2023 Sep;9(1):1-10 IF ; Human . 37704618

[IF=6.208] Akiko Sato. et al. Pharmacological Activation of YAP/TAZ by Targeting LATS1/2 Enhances Periodontal Tissue Regeneration in a Murine Model. INT J MOL SCI. 2023 Jan;24(2):970 WB ; Mouse . 36674487